Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Cetuximab in Advanced Solid Tumors and NSCLC
NCT00408499Phase 2Completed
- Sponsor
- University of California, Davis
- Start
- Aug 2006
- Primary completion
- Apr 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, KL-140 in solid tumor, non-small cell lung cancer (NSCLC), sponsored by University of California, Davis. Started Aug 2006; status: completed.
02
Drugs
erlotinibKL-140
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00408499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00408499.